ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

DOW JONES NEWSWIRES Endo Pharmaceuticals Holdings Inc.'s (ENDP) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation settlement, while the pharmaceutical company reported revenue grew with a boost from a recent acquisition. Endo has seen its revenue rise in recent quarters, aided by acquisitions that expanded its generic-drug business and core painkiller franchise. But the related charges have hurt its bottom line of late. First-quarter sales were expected to be affected by a temporary shutdown of a Novartis AG (NVS, Z.NOV) plant in Nebraska to address potential packaging errors. The plant manufactures some Endo products such as its Opana ER painkiller. In the latest period, Opana ER sales were down 4.2%. On Tuesday the company said Opana ER and Voltaren Gel now in steady supply. Endo reported a loss of $87.3 million, or 75 cents a share, compared with a year-earlier profit of $55.8 million, or 46 cents a share. Excluding impacts from a 2010 litigation settlement with Impax Laboratories Inc. (IPXL), adjusted earnings were down at 87 cents from $1. The company in February expected earnings below 90 cents amid a temporary shutdown at the Novartis plant. Revenue increased 23% to $691 million, with a boost from its American Medical Systems acquisition. Analysts polled by Thomson Reuters most recently projected $702 million. Gross margin fell to 47.2% from 58.7%. Sales of Lidoderm, which makes up the biggest chunk of Endo's top line, were up 11%. Overall branded drug sales were down 3% while generics sales increased 8%. Shares of Endo, which reaffirmed its 2012 guidance, closed Monday at $35.14 and were inactive premarket. The stock is down roughly 10% in the past year. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
05/29/201508:08:02Is This Pfizer's Next Move?
05/27/201511:20:02Stocks To Buy For 10 Years: Facebook Inc, Amazon.com, Inc, and...
05/23/201512:03:02Billionaire George Soros Just Sold These 3 Stocks: Should You?
05/23/201509:09:02Will Competition Cause Teva Pharmaceutical Industries ltd. To...
05/17/201513:02:02Could This Be Healthcare's $158 Billion Black Swan Event?
05/17/201509:05:022 Stocks With Jaw-Dropping Growth Potential
05/12/201510:26:025 Largest Markets for Pharmaceuticals
05/11/201511:40:11Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/08/201515:04:02GlaxoSmithKline PLC Earnings: Pay No Attention to the Results...
05/08/201511:12:03The Best Fidelity Mutual Funds
05/07/201513:40:20Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/07/201513:34:24Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/06/201518:01:31ADR Shares End Mixed; Anheuser-Busch InBev Rises
05/06/201508:50:06GSK Cuts Return to Holders From Novartis Asset Swap
05/06/201507:58:20Genmab 1Q Sales of Arzerra Leukaemia Drug at GBP11.1 Million
05/04/201519:22:23Generic Drugs Grab Growing Market Share in Mexico--Update
05/04/201519:22:11Generic Drugs Grab Market Share in Mexico
05/04/201511:57:01Why Shares in Array BioPharma, Inc. Are Soaring Higher
05/02/201510:41:02The Best Way to Invest Money in Silicon Valley
05/01/201514:49:19Waiting for Exelixis, Inc.'s Meteor to Land

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad